Louis Garguilo Articles
-
Nothing To See Here! Just Big Pharma Investments In China
4/22/2024
WuXi AppTec assists U.S.-based biotechs to develop and supply drugs to U.S. patients. Western-based Pharma assists the development of China's industry, the China Communist Party (CCP) by extension, and patients there. Guess which is under assault? Chief Editor Louis Garguilo tries to figure it all out.
-
CDMOs Pelted By Slings And Arrows
4/18/2024
Chief Editor Louis Garguilo thought he was precipitating a frontal assault by canvassing the Outsourced Pharma Editorial Advisory Board with questions such as: When outsourcing development and manufacturing, what are the challenges, and where are your pain points? But before anyone claims “one-sided,” please read on.
-
A Good Feeling ($$) About Contract Manufacturing
4/15/2024
Occasionally, we look at revenue numbers assigned to the collective activities we focus on at Outsourced Pharma: drug development and manufacturing outsourcing, and working with CDMOs. And we also can provide some pep talks, too.
-
You Want To Rein In China? Then Actually Do It
4/12/2024
Chief Editor Louis Garguilo takes a hard look at proposed legislation H.R. 7085 - the BIOSECURE Act - and draws out some interesting angles and conclusions regarding the biopharma battle between the U.S. and China.
-
Stop Fixating On CDMO Pricing!
4/8/2024
You may have an ill-advised idée fixe on the prices your CDMO is charging you. Who says? Among others, members of our Outsourced Pharma Editorial Advisory Board – a practical and practiced assembly of successful outsourcing professionals. And they start with an offensive C-suite.
-
From Ally To Adversary: BIO's Swift Rebuke Of WuXi
4/5/2024
The CEO of the Biotechnology Innovation Organization (BIO) spearheading expulsion of WuXi Apptec relied on WuXi Biologics as CEO of the biotech he founded. More on this and some breaking news on the U.S. government's accusations regarding WuXi, from Chief Editor Louis Garguilo.
-
Gene Circuits And Biofabs: Building The Evolution
4/1/2024
Can’t find a bio fabrication plant for your gene circuits? Chief Editor Louis Garguilo has located a candidate. It arrives in a for-contract, state-of-the-art capability being carved out by an emerging biopharma. Circuits and biofab described within.
-
Outsourcing Through An Industry-Government Battle
3/25/2024
A PhRMA survey concludes 63% of member companies expect to shift at least some of their r&d investment away from small molecules as a result of the new legislation called the Inflation Reduction Act (IRA). But a lot of this movement has been ongoing for almost 20 years. So what's the real scene, as the industry and government are at loggerheads.
-
Impacts Of The Inflation Reduction Act (IRA)
3/18/2024
Jesse Mendelsohn, a "pharmaceutical regulatory compliance and government pricing” guru, who manages a life sciences group of over 100 consultants, says currently the biggest disruptor to our industry in 2004 is the Inflation Reduction Act (IRA), the 2023 legislation passed by Congress and signed into law by President Biden.
-
BIO Expels WuXi, Agrees With U.S. Government
3/14/2024
“BIO is taking steps now to separate from WuXi-AppTec regarding membership in the organization," says Biotechnology Innovation Organization President & CEO John F. Crowley. But to Chief Editor Louis Garguilo, this seems like a strange company to target.